Neuroprotective Amide Form Hexapeptide HLDF-6, API

COOPERATION OPTIONS

LICENSE

FROM 142 MILLION RUR

RESEARCH PARTNERSHIP

FROM 50 MILLION RUR

more detail

ABOUT THE PROJECT

Neuroprotective Amide Form Hexapeptide HLDF-6, API

A NEW CLASS OF DRUGS FOR THERAPY OF ALZHEIMER'S DISEASE AND ISCHEMIC STROKES.

The product is based on a naturally occurring hexapeptide. It is a fragment of a natural protein - differentiation factor, presented in blood and CNS of mammals and humans. Whereas it penetrates through the blood-brain barrier it can be used as intranasal form.
The peptide surpasses other drugs (nootropics and acetylcholinesterase inhibitors) in terms of neuroprotective effect and influence on reparative and restorative processes, plasticity and trophic provision of the brain.  

Stage of development

NEUROPROTECTIVE AMIDE FORM HEXAPEPTIDE HLDF-6, API

COOPERATION OPTIONS

LICENSE

FROM 142 MILLION RUR

RESEARCH PARTNERSHIP

FROM 50 MILLION RUR

more detail

ABOUT THE PROJECT

NEUROPROTECTIVE AMIDE FORM HEXAPEPTIDE HLDF-6, API

A NEW CLASS OF DRUGS FOR THERAPY OF ALZHEIMER'S DISEASE AND ISCHEMIC STROKES.

The product is based on a naturally occurring hexapeptide. It is a fragment of a natural protein - differentiation factor, presented in blood and CNS of mammals and humans. Whereas it penetrates through the blood-brain barrier it can be used as intranasal form.
The peptide surpasses other drugs (nootropics and acetylcholinesterase inhibitors) in terms of neuroprotective effect and influence on reparative and restorative processes, plasticity and trophic provision of the brain.  

Stage of development

STAGE OF DEVELOPMENT
& RESULTS OF INTELLECTUAL ACTIVITY STATUS


Description

Can be used as API for neurodegenerative and cerebrovascular diseases therapy drugs creation, including treatment of Alzheimer's disease and ischemic stroke.

Description: Dry powder/liofilizate for intranasal dosage forms preparation.

Storage: +4 C.

Possible applications

  • Intellectual and mental disorders associated with brain lesions of various genesis
  • Consequences of craniocerebral injuries, neurosurgical interventions, stroke, chronic cerebral circulatory disorders 
  • As a preventive agent to prevent stroke and neurological disorders

BENEFITS

Has a strong therapeutic effect
BROAD SPECTRUM OF COMBINED NOOTROPIC AND NEUROPROTECTIVE ACTIVITy
EFFICIENCY IN SMALL AND ULTRA-LOW DOSES
NON-TOXIC, SAFE IN USE
EASY ADMINISTRATION ROUTE (INTRANASAL)
HIGH BIOAVAILABILITY OF THE DRUG 

COOPERATION OPTIONS

Options for project implementation include Intellectual Property license agreement and/or further product development together with investor.
license agreement 

Conclusion of agreements on disposal of exclusive intellectual property rights (license agreements). 

Approximate investment amount: 

• Granting the right to use results of intellectual activity - from RUB 142 million RUR

• Royalty 5%

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to bring research to the market launching stage and to organize product manufacturing and sales.

Approximate investment amount: 

Starting at 370 million RUR 

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to reach the further research stage(s) and to sale of the scientific product in the form of sublicensing.

Approximate investment amount:

• Clinical trials, phase 1
Starting at 50 million RUR

• Clinical trials, phase 2
Starting at 100 million RUR

• Clinical trials, phase 3
Starting at 150 million RUR

investment partnership agreements

Conclusion of investment partnership agreements for further research stages on the investor basis with the participation of IBCh RAS.

The aim: to obtain a scientific product or "ready to market" product.

Approximate investment amount: 

• Clinical trials, phase 1
Starting at 50 million RUR

• Clinical trials, phase 2
Starting at 100 million RUR

• Clinical trials, phase 3
Starting at 150 million RUR

• Start manufacturing
Starting at 20 million RUR

• Promotion activities
Starting at 50 million RUR

DEVELOPERS

The Shemyakin & Ovchinnikov Institute of bioorganic chemistry (IBCh) of the Russian Academy of Sciences is one of the largest Russian scientific organizations. The Institute is a leader in fundamental and innovative researches on the fields of molecular, structural and cell biology, bioorganic chemistry, biophysics, bioengineering, cell technologies, “in vivo” molecular based bioimaging, genome editing, bioinformatics etc. This multidisciplinary structure allows large-scale research at the interface of sciences, where the most interesting scientific discoveries are born today.

The hallmark of the IBCh RAS is the concentration of efforts and resources on solving the most urgent and complicated problems on the field of life sciences. Talented young people and leading specialists, including Russian and foreign science leaders, Nobel Prize laureates and members of the international advisory council of the Institute are involved in.

PROJECT TEAM 

Dr. of Sc.

Valeriy Lipkin


PhD

Anna Bogachuk


PHD

Iryna Kostanjan

АВТОР РАЗРАБОТКИ

ЛИПКИН
ВАЛЕРИЙ МИХАЙЛОВИЧ

Член-корреспондент РАН, профессор Доктор химических наук

Российский ученый. Ведущий специалист в области химии белков и пептидов.

Награды и премии: Орден Дружбы Народов, Государственная премия в области науки и техники, Премии РАН имени Ю.А.Овчинникова и именная золотая медаль.

 


PUBLICATIONS

Comparative study of the neuroprotective and nootropic activities of the carboxylate and amide forms of the HLDF-6 peptide in animal models of Alzheimer's disease

Anna P Bogachouk, Zinaida I Storozheva, Olga A Solovjeva, Vyacheslav V Sherstnev, Yury A Zolotarev, Vyacheslav N Azev, Igor L Rodionov, Elena A Surina, Valery M Lipkin

The Qualitative Analysis of the Amide Derivative of HLDF-6 Peptide and Its Metabolites with the Use of Tritium- and Deuterium-Labeled Derivatives

A Zolotarev, A K Dadayan, N V Kost, M E Voevodina, O Y Sokolov, V S Kozik, S I Shram, V N Azev, E V Bocharov, A P Bogachouk, V M Lipkin, N F Myasoedov

Influence of Subchronic Administration of the HLDF-6 Peptide on an Efficacy of the Exploratory Behavior of Inbred Mice of the Balb/c and C57Bl/6 Strains

Georgy I Kovalev, E. V. Vasil’eva, Ramiz M Salimov,Yu. A. Zolotarev, A. K. Dadayan, A. P. Bogachouk, Valery Lipkin

Specific activity of the amide form of HLDF-6 peptide: study in a transgenic model of Alzheimer's disease

Comparative study of carboxylate and amide forms of HLDF-6 peptide: Neuroprotective and nootropic effects in animal models of ischemic stroke

Аnna P Bogachuk, Zinaida I Storozheva, Andrey Т Proshin, Vyacheslav V Sherstnev, Irina V Smirnova, Tatyana M Shuvaeva, Valery M Lipkin

Development of a new neuroprotector based on HLDF-6 peptide

CONTACT us

get in touch

On cooperation issues please contact the head of NTI Center project department
Sergey Semenov
E-mail consortium@cnti-ibch.ru
address 16/10, Miklukho-Maklaya St, Moscow, Russian Federation, 117997
All products and services of NTI Center IBHh RAS
view more
Report abuse